Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Puts “Mind Towards” Phase III For CETP Inhibitor

Executive Summary

Roche is leaning in favor of initiating a Phase III study of its cholesteryl ester transfer protein inhibitor, R1658, after conducting an in-depth analysis of data, evaluating information on Pfizer's failed torcetrapib and consulting experts

You may also be interested in...



ESA Labeling Should Explain Hemoglobin Target, Advisory Committee Says

Treatment targets for erythropoiesis-stimulating agents in the renal setting need to be accompanied by clinical management information, FDA's Cardiovascular and Renal Drugs and Drug Safety and Risk Management Advisory Committees says

Amgen Wins Round in Battle to Keep Roche’s EPO Off Market

Amgen has the edge as its patent battle against Roche goes to trial this week since the federal judge overseeing the dispute found that Roche's anti-anemia drug Mircera infringes a key Amgen patent

Galvus Trial To Take Longer Than Predicted; Novartis Also Sees Tasigna Delay

Novartis is now facing a longer delay for its dipeptidyl peptidase-4 agent Galvus (vildagliptin) than previously predicted, since the safety study in patients with renal impairment requested by FDA will take at least six months, not "weeks" as originally suggested

Related Content

UsernamePublicRestriction

Register

PS048923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel